NCT05784688
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05784688
Title Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors TiumBio Co., Ltd.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
NEXT Oncology ACTIVE_NOT_RECRUITING San Antonio Texas 78229-3307 United States Details
Hope Cancer Center ACTIVE_NOT_RECRUITING Tyler Texas 75701 United States Details
Medical Oncology ACTIVE_NOT_RECRUITING Spokane Washington 99208 United States Details
CHA University Bundang Medical Center RECRUITING Seongnam South Korea Details
Seoul National University Bundang Hospital RECRUITING Seongnam South Korea Details
Asan Medical Center RECRUITING Seoul South Korea Details
Samsung Medical Center RECRUITING Seoul South Korea Details
Seoul National University Hospital RECRUITING Seoul South Korea Details
Severance Hospital RECRUITING Seoul South Korea Details
The Catholic University of Korea Seoul St. Mary Hospital RECRUITING Seoul South Korea Details
The Catholic University of Korea St. Vincent's Hospital RECRUITING Suwon South Korea Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field